Harold J. Burstein, MD, PhD, a medical oncologist at the Dana-Farber Cancer Institute, explains how ovary suppression is done in patients with breast cancer. This is a particularly important treatment for younger women who still wish to have children one day.
Harold J. Burstein, MD, PhD, a medical oncologist at the Dana-Farber Cancer Institute, explains how ovary suppression is done in patients with breast cancer. This is a particularly important treatment for younger women who still wish to have children one day.
Ovary suppression can be done in 1 of 2 ways, and both have proven successful in a number of cases and trials. The first option is to completely remove the ovaries surgically. This is not the preferred method, but it has become a standard when a patient does not wish to continue with the second option.
The other way to perform ovary suppression involves gonadotropin-releasing hormone (GnRH) agonist drugs given via injections monthly or once every 3 months. The is typically used first in younger women and tolerance to the drugs will be displayed between 6-12 months of the initial shot. From there, patients can choose to stay on this treatment plan or have the ovaries surgically removed.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen